The healthcare analytics and Real World Evidence (RWE) market in India is expanding rapidly, driven by growing digitization, increased pharma spending on marketing and R&D, and the rising need for data-driven insights. The market for RWE solutions is projected to reach $0.9 billion in 2018 in India, encompassing drug development, repurposing, and pharma marketing. The sector is growing significantly due to the increasing adoption of Electronic Medical Records (EMR), cloud-based data storage, and the regulatory push for digitized healthcare. The cost pressures on pharmaceutical companies and the need for more efficient marketing and clinical trial processes make this market ripe for innovation.

HealthPlix addresses critical pain points in the pharma and healthcare sector by offering a tech-enabled EMR platform that streamlines data capture, improves clinical efficiency, and provides real-time insights. Its RWE dashboard enables pharma companies to leverage anonymized patient data to optimize drug positioning, marketing strategies, and clinical trial efficiency. By integrating RWE into drug development and marketing processes, Healthplix reduces R&D costs by 10-15% and its SaaS-based model, monetized through recurring licenses, ensures scalability and stability.

The founders’ focus on enhancing data capture and building longitudinal patient records gives HealthPlix a significant competitive advantage. Our investment is driven by HealthPlix’s potential to disrupt the fragmented healthcare data landscape, and its ability to drive pharma efficiency. With a strong growth trajectory, HealthPlix is poised to become a leader in India’s healthcare analytics and RWE sector, and we are thrilled to be a part of their journey.